News
BITRF
0.0027
NaN%
--
Weekly Report: what happened at BITRF last week (0609-0613)?
Weekly Report · 5d ago
Biotron Announces Change of Share Registry Address
TipRanks · 6d ago
Weekly Report: what happened at BITRF last week (0602-0606)?
Weekly Report · 06/09 11:04
Weekly Report: what happened at BITRF last week (0526-0530)?
Weekly Report · 06/02 11:11
Weekly Report: what happened at BITRF last week (0519-0523)?
Weekly Report · 05/26 11:10
Biotron Limited Announces Investor Webinar to Discuss Recent Developments
TipRanks · 05/23 01:07
Weekly Report: what happened at BITRF last week (0512-0516)?
Weekly Report · 05/19 11:02
Weekly Report: what happened at BITRF last week (0505-0509)?
Weekly Report · 05/12 11:02
Weekly Report: what happened at BITRF last week (0428-0502)?
Weekly Report · 05/05 11:04
Biotron Limited Announces Change in Company Secretary
TipRanks · 05/02 04:07
Weekly Report: what happened at BITRF last week (0421-0425)?
Weekly Report · 04/28 11:13
Biotron Limited Advances Antiviral Commercialization with New Funding and Strategic Partnerships
TipRanks · 04/24 00:19
Weekly Report: what happened at BITRF last week (0414-0418)?
Weekly Report · 04/21 11:13
Weekly Report: what happened at BITRF last week (0407-0411)?
Weekly Report · 04/14 11:03
Biotron Limited Announces Director’s Interest Change
TipRanks · 04/10 02:27
Biotron Limited Completes Successful Rights Issue to Fund Antiviral Programs
TipRanks · 04/08 00:28
Weekly Report: what happened at BITRF last week (0331-0404)?
Weekly Report · 04/07 11:02
Weekly Report: what happened at BITRF last week (0324-0328)?
Weekly Report · 03/31 11:13
Weekly Report: what happened at BITRF last week (0317-0321)?
Weekly Report · 03/24 11:02
Weekly Report: what happened at BITRF last week (0310-0314)?
Weekly Report · 03/17 11:12
More
Webull provides a variety of real-time BITRF stock news. You can receive the latest news about Biotron through multiple platforms. This information may help you make smarter investment decisions.
About BITRF
Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.